Global Skeletal Dysplasia Market, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2029
“Skeletal Dysplasia Market” is the title of an upcoming report at MarketResearch.biz. Vital data and information related to the global skeletal dysplasia market are to be presented in the report. In order to ensure accuracy and facts before presenting the final report, all possible scenarios and outcomes are examined based on current scenarios. In addition, data and information gathered is verified by experts in the field, and then included in the report. The market research report also presents deep insights into growth factors, restraints, Y-o-Y growth rates, major trends, forecasts, and opportunities. Details of key players, geographic footprint, operating segments, and contact details are included in the company profile section of the report. The report is segmented on the basis of type, treatment, and regions and countries.
A varied group of more than 450 disorders in the skeleton is known as skeletal dysplasia. These disorders are related to the development of either cartilage or bones. Skeletal dysplasia can affect any part of the skeleton with abnormalities related to bone shape, size, density, and short stature. The cause of this disorder is disturbance in growth of bones at the early stages of fetal development.
Among some of the major factors expected to drive growth of the market are presence of pipeline products and commercialization of novel drugs. Increasing prevalence of skeletal dysplasia is projected to continue result in new and more effective drugs and therapies. The SKELDYS.ORG and Fetal Medicine Foundation are online portals, which provide information on diagnosis and available treatment options for different types of skeletal dysplasia. Moreover, emerging advanced drug therapies for treatment is projected to significantly contribute to growth of the global skeletal dysplasia market over the forecast period. One of the promising therapeutic options available is gene therapy, which involves cell-based therapy and allele silencing. Other factors expected to contribute to growth of the market are increasing prevalence of birth defects and congenital disorders. According to the Center for Disease Control & Prevention (CDC), in the US, one in every 33 babies is affected due to birth defects each year. Increasing number of genetic disorders and growing R&D activities for drug development are also projected to drive growth of the market over the forecast period. Moreover, increasing consumption of alcohol, cigarettes, and changing lifestyle are also significantly contributing to growth of the market. However, ignorance of people about the disease is projected to hamper growth of the market. Development and introduction of new drugs is expected to create growth opportunities for key players operating in the global market over the forecast period.
Skeletal Dysplasia Market Segment Analysis:
By Type: The hypophosphatasia segment continues to dominate the global skeletal dysplasia market in terms of revenue share among other type segments. This can be attributed to increasing prevalence of hypophosphatasia. The fibrodysplasia ossificans progressive segment is expected to register fastest revenue growth over the forecast period, and this is attributed to increasing awareness of the disease and presence of pipeline products.
By Treatment: The surgery segment among the treatment segments is expected to continue its dominance in terms of revenue share over the forecast period. This can be attributed to effectiveness of this treatment, especially for types including hypophosphatasia and achondroplasia. In addition, more patients prefer surgery over medication owing to faster outcomes from this option. The medication segment is projected to register fastest revenue growth over the forecast period, which is attributed to increasing initiative to develop novel drugs.
Skeletal Dysplasia Market Regional Analysis:
Europe is projected to dominate the global skeletal dysplasia market in terms of revenue share over the forecast period. Dominance of the region is attributed to increasing adoption of surgeries and awareness about the disease. Revenue from the market in North America is expected to increase significantly owing to increasing R&D initiatives to develop more effective drugs. Owing to relatively lower prevalence of the disease, the Asia Pacific market currently accounts for a lower revenue share in the global market.
Global Skeletal Dysplasia Market Segmentation:
- X-linked hypophosphatemia
- Fibrodysplasia ossificans progressive
- Multiple osteochondromas
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Particular Scope Region
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- South Africa
- Rest of Middle East and Africa
Actual Year 2020 Estimated Year 2021 Forecast Period 2021–2030 Revenue in US$
- Reddy’s Laboratories
- Celgene Corporation
- Teva Pharmaceutical Industries
- Hoffmann-La Roche AG
- Merck Group
- Abbott Laboratories
- Eli Lilly and Company
- Novartis AG
- Cipla Inc.
- Clementia Pharmaceuticals
- BioMarin Pharmaceutical, Inc.
- Regeneron Pharmaceutical, Inc.
Request for TOC
Request for Customization
Don't just take our word. We are trusted by these great companies!